AboutPortfolioInvestment FocusLeadershipInsightsContact Partner With Us
Leadership

The Minds Behind
MedLinks Capital

Our team combines decades of healthcare investing, clinical science, and operational leadership — united by a shared belief that extraordinary outcomes begin with extraordinary people.

Core Team

Our People

Dr. Harry R. Jacobson
Dr. Harry R. Jacobson
Chairman & Strategic Advisor
Physician, entrepreneur, and investor with five decades of healthcare leadership. As CEO of Vanderbilt University Medical Center (1997–2009), grew revenue from $750M to $2.25B and achieved a top-10 NIH funding ranking. Co-founder of Renal Care Group (NYSE, acquired by Fresenius), Contact Software (acquired by Symantec), and CeloNova Biosciences — with a product line sold to Boston Scientific for up to $270M. Former board member of Merck and KCI; elected to the National Academy of Sciences and Tennessee Healthcare Hall of Fame.
Gurdev Chimni
Gurdev Chimni
Founder & CEO
Strategic relationship builder and healthcare-focused investor with a deep North American network spanning family offices, healthcare executives, and institutional stakeholders. At MedLinks Capital, Gurdev leads deal origination, capital formation, and strategic partnership facilitation across healthcare services, biotechnology, and medical innovation — with investments including Gradalis (oncology immunotherapy), Virtuoso Surgical (FDA Breakthrough Device designation), and Lobe Sciences. A former professional golfer who competed internationally, he brings a relationship-first philosophy shaped by years in high-performance environments.
Andrew Jacobson
Andrew Jacobson
Managing Partner
Healthcare investor, co-founder, and capital markets strategist with $32M+ raised across real estate, software, healthcare services, and biotechnology. Andrew has co-founded or led capital raises for MedLogic ($3.25M raised, $65M in claims receivables), CNS Biosciences (Emeramide/Irminix® Phase 2, targeting Progressive Supranuclear Palsy and Parkinson's), Gradalis (FDA RMAT-designated personalised cancer immunotherapy, Phase 3-ready), and Virtuoso Surgical (FDA Breakthrough Device designation). His expertise spans entity formation, exclusive licence negotiation, and cross-border capital facilitation across a high-conviction life sciences portfolio.
Advisory Board

World-Class Advisors

Our advisory board brings together global leaders in real estate, pharmaceutical science, and strategic investment — each bringing a rare combination of operational depth and capital markets expertise that opens doors at the highest levels.

Ramsey Shaheen
Global Real Estate Visionary & Strategic Healthcare Investor

Ramsey Shaheen operates at a level few reach. As President of Cachet Homes, he commands one of Southern Ontario's most powerful residential development empires — delivering over 1,000 homes annually across master-planned communities that have redefined the standard of modern living. With four decades of brand equity behind him and a pipeline that rivals some of the most prolific builders in North America, Ramsey's name is synonymous with scale, sophistication, and enduring value.

For over 15 years, Ramsey has been an active and deeply connected investor in the healthcare space — cultivating relationships, evaluating complex deals, and backing opportunities at the cutting edge of medical innovation. His fluency in both industries gives him a perspective that is exceptionally rare: the discipline of a large-scale operator combined with the instincts of a seasoned capital allocator. Those who work with Ramsey understand quickly that they are dealing with someone who thinks in decades, not quarters.

Dr. Fred Sancilio
Pioneering Scientist & Serial Entrepreneur in Global Drug Development

Dr. Fred Sancilio is not simply a figure in the pharmaceutical world — he is one of its architects. With over 40 years of experience navigating the most demanding corridors of drug development, clinical science, and regulatory strategy, Dr. Sancilio has built, scaled, and exited companies that have reshaped how the industry thinks about bringing transformative medicines to market. His track record speaks in a language sophisticated investors understand immediately: drugs approved, deals closed, and big pharma writing the checks.

Today, as the driving force behind Lobe Sciences, Dr. Sancilio is once again at the frontier. Under his leadership, Lobe has engineered a stabilised, non-hallucinogenic form of psilocin — patented through 2041 — now advancing through FDA clinical trials with Phase 2 fully funded. The pipeline extends further into rare blood disorders, with a compound showing a 43% reduction in painful crises in a market left wide open after Pfizer's $5 billion drug was withdrawn.